Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 6/2016

01-12-2016 | Review Article

Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer

Authors: Radmila Lemstrova, Bohuslav Melichar, Beatrice Mohelnikova-Duchonova

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2016

Login to get access

Abstract

Most patients with pancreatic ductal adenocarcinoma (PDAC) present with unresectable or metastatic disease with very poor prognosis. Chemotherapy is the primary treatment modality for patients with locally advanced and metastatic PDAC, but the efficacy of currently available regimens is limited. Taxanes are widely used in many primary cancers including breast, ovarian and lung cancers. The activity of combined regimen of taxanes plus nucleoside analogue or platinum derivate in terms of response rate ranges between 20 and 57 % in PDAC and may prolong overall survival. Since 2013 nab-paclitaxel (paclitaxel-albumin-bound particles) became a new treatment option for patients with metastatic pancreatic cancer based on the results of MPACT trial. Moreover, encouraging activity in PDAC of the combination regimen of paclitaxel and carboplatin that is being widely used in other solid tumors has been reported recently. Biomarkers, including biomarkers predictive of taxane resistance, could allow individualized tailored therapy. BRCA mutation status could serve as predictor of better chemotherapy treatment outcome in PDAC. The present review summarizes the principal clinical trials evaluating the efficacy of taxanes both as monotherapy and in combination in view of the potential use in the treatment of PDAC.
Literature
1.
Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6):2403–2413PubMed
2.
Deplanque G, Demarchi M, Hebbar M, Flynn P, Melichar B, Atkins J, Nowara E, Moyé L, Piquemal D, Ritter D, Dubreuil P, Mansfield CD, Acin Y, Moussy A, Hermine O, Hammel P (2015) A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer. Ann Oncol 26(6):1194–1200CrossRefPubMedPubMedCentral
3.
Fuchs CS, Azevedo S, Okusaka T, Van Laethem JL, Lipton LR, Riess H, Szczylik C, Moore MJ, Peeters M, Bodoky G, Ikeda M, Melichar B, Nemecek R, Ohkawa S, Świeboda-Sadlej A, Tjulandin SA, Van Cutsem E, Loberg R, Haddad V, Gansert JL, Bach BA, Carrato A (2015) A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial. Ann Oncol 26(5):921–927CrossRefPubMedPubMedCentral
4.
Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M, Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817–1825CrossRefPubMed
5.
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691–1703CrossRef
6.
Bekaii-Saab T, Noonan AM, Lesinski G, Mikhail S, Ciombor K, Pant S, Aparo S, Tahiri S, Thompson A, Sexton J, Marshall JL, Mace T, Wu C, El-Rayes B, Timmers C, Geyer S, Zwiebel J, Villalona-Calero MA (2014) LBA19A multi-institutional randomized phase 2 trial of the oncolytic virus reolysin in the first line treatment metastatic adenokarcinoma of the pancreas (MAP). Ann Oncol 25(Suppl. 4):mdu438-19
7.
Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277(5698):665–667CrossRefPubMed
8.
Lavelle F, Fizames C, Gueritte-Voegelein F, Guenard D, Potier P (1989) Experimental properties of RP 56976, a taxol derivative. Proc Am Assoc Cancer Res 30:2254
9.
Bissery MC, Guénard D, Guéritte-Voegelein F, Lavelle F (1991) Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 51(18):4845–4852PubMed
10.
Qi WX, Shen Z, Lin F, Sun YJ, Min DL, Tang LN, He AN, Yao Y (2013) Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. Curr Med Res Opin 29(2):117–125CrossRefPubMed
11.
Blagosklonny MV, Schulte T, Nguyen P, Trepel J, Neckers LM (1996) Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 56(8):1851–1854PubMed
12.
Huang Y, Johnson KR, Norris JS, Fan W (2000) Nuclear factor-κB/IκB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. Cancer Res 60(16):4426–4432PubMed
13.
Kumar GN, Walle UK, Bhalla KN, Walle T (1993) Binding of taxol to human plasma, albumin and alpha-1-acid glycoprotein. Res Commun Chem Pathol Pharmacol 80(3):337–344PubMed
14.
Urien S, Barré J, Morin C, Paccaly A, Montay G, Tillement JP (1996) Docetaxel serum protein binding with high affinity to alpha1-acid glycoprotein. Invest New Drugs 14(2):147–151CrossRefPubMed
15.
Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ, Franke RM, Hu S, Schuetz EG, Lamba V, Messersmith WA, Wolff AC, Carducci MA, Sparreboom A (2009) Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther 85(2):155–163CrossRefPubMed
16.
Tanino T, Nawa A, Nakao M, Noda M, Fujiwara S, Iwaki M (2009) Organic anion transporting polypeptide 2 mediated uptake of paclitaxel and 2′ ethylcarbonate linked paclitaxel in freshly isolated rat hepatocytes. J Pharm Pharmacol 61(8):1029–1035PubMed
17.
Woo JS, Lee CH, Shim CK, Hwang SJ (2003) Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. Pharm Res 20(1):24–30CrossRefPubMed
18.
Su GM, Davey MW, Davey RA (1998) Induction of broad drug resistance in small cell lung cancer cells and its reversal by paclitaxel. Int J Cancer 76(5):702–708CrossRefPubMed
19.
Brooks TA, Minderman H, O’Loughlin KL, Pera P, Ojima I, Baer MR, Bernacki RJ (2003) Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol Cancer Ther 2(11):1195–1205PubMed
20.
Huisman MT, Chhatta AA, van Tellingen O, Beijnen JH, Schinkel AH (2005) MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer 116(5):824–829CrossRefPubMed
21.
Guitton J, Cohen S, Tranchand B, Vignal B, Droz JP, Guillaumont M, Manchon M, Freyer G (2005) Quantification of docetaxel and its main metabolites in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 19(17):2419–2426CrossRefPubMed
22.
Sonnichsen DS, Relling MV (1994) Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet 27(4):256–269CrossRefPubMed
23.
Shord SS, Faucette SR, Gillenwater HH, Pescatore SL, Hawke RL, Socinski MA, Lindley C (2012) Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 51(4):328–336
24.
Frese KK, Neesse A, Cook N, Bapiro TE, Lolkema MP, Jodrell DI, Tuveson DA (2012) nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov 2(3):260–269CrossRefPubMedPubMedCentral
25.
Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4(4):1013–1019PubMed
26.
Gelderblom H, Verweij J, Nooter K, Sparreboom A (2001) Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37(13):1590–1598CrossRefPubMed
27.
Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR Jr, Van Echo DA, Von Hoff DD, Leyland-Jones B (1990) Hypersensitivity reactions from taxol. J Clin Oncol 8(7):1263–1268PubMed
28.
Ten Tije A, Verweij J, Loos WJ, Sparreboom A (2003) Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 42(7):665–685CrossRefPubMed
29.
van Tellingen O, Huizing MT, Panday VR, Schellens JH, Nooijen WJ, Beijnen JH (1999) Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer 81(2):330CrossRefPubMedPubMedCentral
30.
Gradishar WJ (2006) Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 7(8):1041–1053CrossRefPubMed
31.
Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, Kim NK, Bang YJ (2004) Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 10(11):3708–3716CrossRefPubMed
32.
Chang HI, Yeh MK (2012) Clinically-proven liposome-based drug delivery: formulation, characterization and therapeutic efficacy. Int J Nanomed 7:49–60
33.
Gebbia N, Gebbia V (1996) Single agent paclitaxel in the treatment of unresectable and/or metastatic pancreatic adenocarcinoma. Eur J Cancer 32(10):1822–1823CrossRef
34.
Whitehead RP, Jacobson J, Brown TD, Taylor SA, Weiss GR, Macdonald JS (1997) Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study. J Clin Oncol 15(6):2414–2419PubMed
35.
Oettle H, Arnold D, Esser M, Huhn D, Riess H (2000) Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs 11(8):635–638CrossRefPubMed
36.
Shukuya T, Yasui H, Boku N, Onozawa Y, Fukutomi A, Yamazaki K, Taku K, Kojima T, Machida N (2010) Weekly paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective study. Jpn J Clin Oncol 40(12):1135–1138CrossRefPubMed
37.
Maeda S, Motoi F, Onogawa T, Morikawa T, Shigeru O, Sakata N, Takadate T, Naitoh T, Rikiyama T, Katayose Y, Egawa S, Unno M (2011) Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study. Int J Clin Oncol 16(5):539–545CrossRefPubMed
38.
Kim YJ, Bang S, Park JY, Park SW, Chung JB, Song SY (2009) Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer. Cancer Chemother Pharmacol 63(3):529–533CrossRefPubMed
39.
Androulakis N, Kourousis C, Dimopoulos MA, Samelis G, Kakolyris S, Tsavaris N, Genatas K, Aravantinos G, Papadimitriou C, Karabekios S, Stathopoulos GP, Georgoulias V (1999) Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study. J Clin Oncol 17(6):1779PubMed
40.
Rougier P, Adenis A, Ducreux M, de Forni M, Bonneterre J, Dembak M, Clouet P, Lebecq A, Baille P, Lefresne-Soulas F, Blanc C, Armand JP (2000) A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer 36(8):1016–1025CrossRefPubMed
41.
Okada S, Sakata Y, Matsuno S, Kurihara M, Sasaki Y, Ohashi Y, Taguchi T (1999) Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Br J Cancer 80(3–4):438CrossRefPubMedPubMedCentral
42.
Fine RL, Fogelman DR, Schreibman SM, Desai M, Sherman W, Strauss J, Guba S, Andrade R, Chabot J (2008) The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol 61(1):167–175CrossRefPubMed
43.
Xenidis N, Chelis L, Amarantidis K, Chamalidou E, Dimopoulos P, Courcoutsakis N, Tentes A, Chiotis A, Prassopoulos P, Kakolyris S (2012) Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study. Cancer Chemother Pharmacol 69(2):477–484CrossRefPubMed
44.
De Jesus-Acosta A, Oliver GR, Blackford A, Kinsman K, Flores EI, Wilfong LS, Zheng L, Donehower RC, Cosgrove D, Laheru D, Le DT, Chung K, Diaz LA Jr (2012) A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. Cancer Chemother Pharmacol 69(2):415–424CrossRefPubMed
45.
Dakik HK, Moskovic DJ, Carlson PJ, Tamm EP, Qiao W, Wolff RA, Abbruzzese JL, Fogelman DR (2012) The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol 69(2):425–430CrossRefPubMed
46.
Reni M, Cereda S, Rognone A, Belli C, Ghidini M, Longoni S, Fugazza C, Rezzonico S, Passoni P, Slim N, Balzano G, Nicoletti R, Cappio S, Doglioni C, Villa E (2012) A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). Cancer Chemother Pharmacol 69(1):115–123CrossRefPubMed
47.
Lutz MP, Van Cutsem E, Wagener T, Van Laethem JL, Vanhoefer U, Wils JA, Gamelin E, Koehne CH, Arnaud JP, Mitry E, Husseini F, Reichardt P, El-Serafi M, Etienne PL, Lingenfelser T, Praet M, Genicot B, Debois M, Nordlinger B, Ducreux MP, EuropeanOrganisation for Research and Treatment of Cancer Gastrointestinal Group (2005) Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group. J Clin Oncol 23(36):9250–9256CrossRefPubMed
48.
Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagyi GN, Ellerhorst JA (2002) Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8(5):1038–1044PubMed
49.
Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, Zhang H, Soon-Shiong P, Shi T, Rajeshkumar NV, Maitra A, Hidalgo M (2011) Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 29(34):4548–4554CrossRef
50.
Von Hoff D et al (2013) Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates. J Clin Oncol 31(15):(suppl; abstr 4005^)
51.
Ko AH, Truong TG, Kantoff E, Jones KA, Dito E, Ong A, Tempero MA (2012) A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer. Cancer Chemother Pharmacol 70(6):875–881CrossRefPubMed
52.
De Jesus-Acosta A, O´Dwyer P, Ramanathan R et al (2014) A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients with untreated metastatic pancreatic ductal adenocarcinoma (PDA). Poster presented at: 2014 Gastrointestinal Cancers Symposium (ASCO-GI) 2014; January 16-18; San Francisco, CA, USA
53.
Sigal D et al. (2013) Association of 2-O, 3-O desulfated heparin (ODSH) plus combination gemcitabine (G)/nab-paclitaxel (A) with preliminary benefit in untreated metastatic pancreatic cancer. J Clin Oncol 31:(suppl 4; abstr 284)
54.
Cubillo A, Jameson M, Grande E et al (2014) A phase 1b study of the anti-cancer stem cell agent demcizumab (DEM, anti-DLL4) and gemcitabine (GEM) with or without nab-paclitaxel in patients with pancreatic cancer. Poster presented at: 2014 Gastrointestinal Cancers Symposium (ASCO-GI) 2014; January 16-18; San Francisco, CA, USA
55.
Isacoff WH, Reber HA, Hines OJ et al (2012) Metronomic therapy with 5-FU, weekly nab-paclitaxel, leucovorin, and oxaliplatin, plus bevacizumab for advanced pancreatic cancer: a phase II study. In: Proceedings of the 48th annual meeting of the American Society of Clinical Oncology (ASCO) 2012; June 1–5; Chicago, IL, USA: Abstract #e14582. http://​abstract.​asco.​org/​AbstView_​114_​100395.​html
56.
Saif MW, Podoltsev NA, Rubin MS, Figueroa JA, Lee MY, Kwon J, Rowen E, Yu J, Kerr RO (2009) Phase II clinical trial of paclitaxel loaded polymeric micelle in patients with advanced pancreatic cancer. Cancer Invest 28(2):186–194CrossRef
57.
Löhr JM, Haas SL, Bechstein WO, Bodoky G, Cwiertka K, Fischbach W, Fölsch UR, Jäger D, Osinsky D, Prausova J, Schmidt WE, Lutz MP, CT4001 Study Group (2012) Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial. Ann Oncol 23(5):1214–1222CrossRefPubMed
58.
Mohelnikova-Duchonova B, Melichar B (2013) Human equilibrative nucleoside transporter 1 (hENT1): do we really have a new predictive biomarker of chemotherapy outcome in pancreatic cancer patients? Pancreatology 13(6):558–563CrossRefPubMed
59.
Lemstrova R, Melichar B, Mohelnikova-Duchonova B (2014) Role of solute carrier transporters in pancreatic cancer: a review. Pharmacogenomics 15(8):1133–1145CrossRefPubMed
60.
Thomas H, Coley HM (2003) Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10(2):159PubMed
61.
Mohelnikova-Duchonova B, Vrana D, Holcatova I, Ryska M, Smerhovsky Z, Soucek P (2010) CYP2A13, ADH1B, and ADH1C gene polymorphisms and pancreatic cancer risk. Pancreas 39(2):144–148CrossRefPubMed
62.
Mohelnikova-Duchonova B, Brynychova V, Hlavac V, Kocik M, Oliverius M, Hlavsa J, Honsova E, Mazanec J, Kala Z, Melichar B, Soucek P (2013) The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer. Cancer Chemother Pharmacol 72(3):669–682CrossRefPubMed
63.
64.
McCarroll JA, Sharbeen G, Liu J, Youkhana J, Goldstein D, McCarthy N, Limbri LF, Dischl D, Ceyhan GO, Erkan M, Johns AL, Biankin AV, Kavallaris M, Phillips PA (2015) III-Tubulin: a novel mediator of chemoresistance and metastases in pancreatic cancer. Oncotarget 6(4):2235–2249CrossRefPubMed
65.
66.
Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, Haber M, Horwitz SB (1997) Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Investig 100(5):1282–1293CrossRefPubMedPubMedCentral
67.
Altieri DC (2003) Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22(53):8581–8589CrossRefPubMed
68.
Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A, Shimosegawa T (2001) Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 92(2):271–278CrossRefPubMed
69.
Kami K, Doi R, Koizumi M, Toyoda E, Mori T, Ito D, Fujimoto K, Wada M, Miyatake S, Imamura M (2004) Survivin expression is a prognostic marker in pancreatic cancer patients. Surgery 136(2):443–448CrossRefPubMed
70.
Ekeblad S, Lejonklou MH, Stålberg P, Skogseid B (2012) Prognostic relevance of survivin in pancreatic endocrine tumors. World J Surg 36(6):1411–1418CrossRefPubMed
71.
Ren YQ, Zhang HY, Su T, Wang XH, Zhang L (2014) Clinical significance of serum survivin in patients with pancreatic ductal adenocarcinoma. Eur Rev Med Pharmacol Sci 18(20):3063–3068PubMed
72.
73.
Apte MV, Wilson JS, Lugea A, Pandol SJ (2013) A starring role for stellate cells in the pancreatic cancer microenvironment. Gastroenterology 144(6):1210–1219CrossRefPubMedPubMedCentral
74.
Dunér S, Lopatko Lindman J, Ansari D, Gundewar C, Andersson R (2010) Pancreatic cancer: the role of pancreatic stellate cells in tumor progression. Pancreatology 10(6):673–681CrossRefPubMed
75.
Bardeesy N, DePinho RA (2012) Pancreatic cancer biology and genetics. Nat Rev Cancer 2(12):897–909CrossRef
76.
Lohse I, Borgida A, Cao P, Cheung M, Pintilie M, Bianco T, Holter S, Ibrahimov E, Kumareswaran R, Bristow RG, Tsao MS, Gallinger S, Hedley DW (2015) BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts. Br J Cancer 113(3):425–432CrossRefPubMedPubMedCentral
77.
Golan T, Kanji ZS, Epelbaum R, Devaud N, Dagan E, Holter S, Aderka D, Paluch-Shimon S, Kaufman B, Gershoni-Baruch R, Hedley D, Moore MJ, Friedman E, Gallinger S (2014) Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 111(6):1132–1138CrossRefPubMedPubMedCentral
78.
Mohelnikova-Duchonova B, Kocik M, Duchonova B, Brynychova V, Oliverius M, Hlavsa J, Honsova E, Mazanec J, Kala Z, Ojima I, Hughes DJ, Doherty JE, Murray HA, Crockard MA, Lemstrova R, Soucek P (2016) Hedgehog pathway overexpression in pancreatic cancer is abrogated by new generation taxoid SB-T-1216. Pharmacogenomics J (in press)
79.
Lam AP, Sparano JA, Vinciguerra V, Ocean AJ, Christos P, Hochster H, Camacho F, Goel S, Mani S, Kaubisch A (2010) Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma. Am J Clin Oncol 33(2):121PubMedPubMedCentral
80.
Cereda S, Reni M (2008) Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer. J Chemother 20(4):509–512CrossRefPubMed
81.
Syrigos KN, Michalaki B, Alevyzaki F, Machairas A, Mandrekas D, Kindilidis K, Karatzas G (2001) A phase-II study of liposomal doxorubicin and docetaxel in patients with advanced pancreatic cancer. Anticancer Res 22(6B):3583–3588
82.
Schneider BP, Ganjoo KN, Seitz DE, Picus J, Fata F, Stoner C, Calley C, Loehrer PJ (2003) Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study. Oncology 65(3):218–223CrossRefPubMed
83.
Saif MW, Syrigos K, Penney R, Kaley K (2010) Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study. Anticancer Res 30(7):2905–2909PubMed
84.
Hosein PJ, de Lima LG, Pastorini VH Jr, Gomez C, Macintyre J, Zayas G, Reis I, Montero AJ, Merchan JR, Rocha Lima CM (2013) A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Am J Clin Oncol 36(2):151–156CrossRefPubMed
85.
Cohen SJ, O’Neil BH, Berlin J, Ames P, McKinley M, Horan J, Catalano PM, Davies A, Weekes CD, Leichman L (2016) A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic Oncology GI Cancer Consortium study. Cancer Chemother Pharmacol 77(4):693–701CrossRefPubMed
Metadata
Title
Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer
Authors
Radmila Lemstrova
Bohuslav Melichar
Beatrice Mohelnikova-Duchonova
Publication date
01-12-2016
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 6/2016
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-016-3058-y

Other articles of this Issue 6/2016

Cancer Chemotherapy and Pharmacology 6/2016 Go to the issue

Original Article

Toxicity, pharmacokinetics and metabolism of a novel inhibitor of IL-6-induced STAT3 activation

Original Article

Dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal carcinomas

Original Article

Lack of effect of smoking status on axitinib pharmacokinetics in patients with non-small-cell lung cancer

Original Article

18F-FLT PET/CT imaging in patients with advanced solid malignancies treated with axitinib on an intermittent dosing regimen

Original Article

Active salvage chemotherapy versus best supportive care for patients with recurrent or metastatic squamous cell carcinoma of the esophagus refractory or intolerable to fluorouracil, platinum, and taxane

Original Article

Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a “European Pediatric Oncology Off-patents Medicines Consortium” trial
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits